Nomura Holdings’s Checkpoint Therapeutics CKPT Stock Holding History

Nomura Holdings’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,610	Closed	-$53K	–	2261
2021 Q3	$53K	Buy	+1,610	New	+$47.6K	﹤0.01%	1838

Other funds holding CKPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nomura Holdings's CKPT Position: Q4 2021 in Review

Nomura Holdings sold out of Checkpoint Therapeutics (CKPT) in Q4 2021, closing a stake of 1,610 shares — an estimated $53K sold.

Nomura Holdings first reported a position in CKPT in Q3 2021 and held it in 1 quarter. The position peaked at $53K in Q3 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q4 2021.

Nomura Holdings reported no remaining Checkpoint Therapeutics position as of Q4 2021 after selling out during the quarter.
Nomura Holdings sold 1,610 Checkpoint Therapeutics shares in Q4 2021, an estimated $53K.
Nomura Holdings first reported a position in Checkpoint Therapeutics in Q3 2021 and held it in 1 quarter.
Nomura Holdings's Checkpoint Therapeutics position peaked at $53K in Q3 2021.
62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2021.

Based on Nomura Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.